Prelude Capital Management’s Derma Sciences, Inc. Common Stock (DE) DSCI Stock Holding History

Prelude Capital Management’s Portfolio DSCI Stock Details DSCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,000	Closed	-$5K	–	2014
2016 Q4	$5K	Hold	1,000	–	–	﹤0.01%	1447
2016 Q3	$5K	Buy	1,000 +600	+150%	+$2.8K	﹤0.01%	1497
2016 Q2	$2K	Buy	+400	New	+$1.5K	﹤0.01%	1526
2015 Q2	–	Sell	-3,400	Closed	-$29K	–	2409
2015 Q1	$29K	Sell	3,400 -300	-8%	-$2.56K	﹤0.01%	1673
2014 Q4	$34K	Buy	3,700 +1,400	+61%	+$12.2K	0.01%	1584
2014 Q3	$19K	Buy	+2,300	New	+$21.3K	﹤0.01%	1745

Other funds holding DSCI

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Prelude Capital Management's DSCI Position: Q1 2017 in Review

Prelude Capital Management sold out of Derma Sciences, Inc. Common Stock (DE) (DSCI) in Q1 2017, closing a stake of 1,000 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in DSCI in Q3 2014 and held it in 6 quarters. The position peaked at $34K in Q4 2014. 1 fund tracked by Wall St. Rank holds DSCI as of Q1 2017.

Prelude Capital Management reported no remaining Derma Sciences, Inc. Common Stock (DE) position as of Q1 2017 after selling out during the quarter.
Prelude Capital Management sold 1,000 Derma Sciences, Inc. Common Stock (DE) shares in Q1 2017, an estimated $5K.
Prelude Capital Management first reported a position in Derma Sciences, Inc. Common Stock (DE) in Q3 2014 and held it in 6 quarters.
Prelude Capital Management's Derma Sciences, Inc. Common Stock (DE) position peaked at $34K in Q4 2014.
1 fund tracked by Wall St. Rank held Derma Sciences, Inc. Common Stock (DE) as of Q1 2017.

Based on Prelude Capital Management's 13F filing for Q1 2017, filed 15 May 2017.